Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H18ClFN4O2 |
Molecular Weight | 448.877 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC(COC2=CC=C(NC3=C4C=C(NC(=O)C=C)C=CC4=NC=N3)C=C2Cl)=CC=C1
InChI
InChIKey=MVZGYPSXNDCANY-UHFFFAOYSA-N
InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)
Molecular Formula | C24H18ClFN4O2 |
Molecular Weight | 448.877 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21789172Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/24612546 | http://adisinsight.springer.com/drugs/800032292
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21789172
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/24612546 | http://adisinsight.springer.com/drugs/800032292
AST-1306, also known as Allitinib, is an orally active potent, selective, irreversible inhibitor of the HER family of receptor tyrosine kinases. AST-1306 inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems. AST1306 potently suppressed tumor growth in ErbB2-overexpressing adenocarcinoma xenograft and FVB-2/N(neu) transgenic breast cancer mouse models. Allitinib is in Phase I clinical trial for the treatment of advanced solid tumors. Serious adverse effects detected were: diarrhea, dehydration and hyperbilirubinemia.
Originator
Sources: http://adisinsight.springer.com/drugs/800032292
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/21789172
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL203 |
0.5 nM [IC50] | ||
Target ID: CHEMBL1824 |
3.0 nM [IC50] | ||
Target ID: CHEMBL3009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21789172 |
0.8 nM [IC50] | ||
Target ID: CHEMBL2111472 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24598282 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. | 2014 Aug 1 |
|
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. | 2014 Sep 29 |
|
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker. | 2016 Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24612546
1000 mg three times daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21789172
The Calu-3 lung adenocarcinoma and BT474 breast cancer cell line, containing high levels of ErbB2, were more sensitive to AST1306, with IC50 values of 0.23 and 0.97 uM/L, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:55:03 GMT 2023
by
admin
on
Sat Dec 16 15:55:03 GMT 2023
|
Record UNII |
CX0M5RO7CY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CX0M5RO7CY
Created by
admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
|
PRIMARY | |||
|
24739943
Created by
admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
|
PRIMARY | |||
|
DTXSID30647124
Created by
admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
|
PRIMARY | |||
|
C179280
Created by
admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
|
PRIMARY | |||
|
897383-62-9
Created by
admin on Sat Dec 16 15:55:04 GMT 2023 , Edited by admin on Sat Dec 16 15:55:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TARGET -> INHIBITOR |
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
AT DAY 1 |
|
||
Biological Half-life | PHARMACOKINETIC |
|
IN CANCER PATIENTS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
THREE TIMES A DAY |
|
||
Tmax | PHARMACOKINETIC |
|
IN CANCER PATIENTS |
|
||